• 1
    Polich J. P300 in clinical application: Meaning, method, and measurement. Am. J. EEG Technol. 1991; 31: 201231.
  • 2
    Blackwood D. P300, a state and a trait marker in schizophrenia. Lancet 2000; 355: 771772.
  • 3
    Mathalon DH, Ford JM, Pfefferbaum A. Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study. Biol. Psychiatry 2000; 47: 434449.
  • 4
    Maeda H, Morita K, Kawamura N, Nakazawa Y. Amplitude and area of the auditory P300 recorded with eyes open reflect remission of schizophrenia. Biol. Psychiatry 1996; 39: 743746.
  • 5
    Iwanami A, Okajima Y, Isono H et al. Effects of risperidone on event-related potentials in schizophrenic patients. Pharmacopsychiatry 2001; 34: 7379.
  • 6
    Gonul AS, Suer C, Coburn K, Ozesmi C, Oguz A, Yilmaz A. Effects of olanzapine on auditory P300 in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 173177.
  • 7
    Purdon SE, Jones DW, Strip E et al. Neuropsychological changes in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry 2000; 57: 249258.
  • 8
    Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 2001; 26: 137149.
  • 9
    Umbricht D, Javitt D, Novak G et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol. Psychiatry 1998; 44: 716725.
  • 10
    Lang SF, Nelson CA, Collins PF. Event-related potentials to emotional and neutral stimuli. J. Clin. Exp. Neuropsychol. 1990; 12: 946958.
  • 11
    Johnston WS, Wang XT. The relationship between menstrual phase and the P3 component of ERPs. Psychophysiology 1991; 28: 400409.
  • 12
    An SK, Lee SJ, Lee CH et al. Reduced P3 amplitude by negative facial emotional photographs in schizophrenia. Schizophr. Res. 2003; 64: 123135.
  • 13
    Yamamoto M, Morita K, Waseda Y et al. Changes in auditory P300 with clinical remission in schizophrenia; Effects of facial-affect stimuli. Psychiatry Clin. Neurosci. 2001; 55: 347352.
  • 14
    Ueno T, Morita K, Shoji Y et al. Recognition of facial expression and visual P300 in schizophrenic patients: Differences between paranoid type patients and non-paranoid patients. Psychiatry Clin. Neurosci. 2004; 58: 585592.
  • 15
    Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotic drugs part XV – dose equivalence of novel neuroleptics: perospirone. Jpn. J. Clin. Psychopharmacol. 2001; 4: 869870.
  • 16
    Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002; 26: 583594.
  • 17
    Kay SR, Opler LA, Fiszbein A. (translated by Yamada H, Matsui K, Kikumoto K) Positive and Negative Syndrome Scale (PANSS) Rating Manual. Seiwa Shoten Publishers, Tokyo, 1991.
  • 18
    Kane JM, Leucht S, Carpenter D et al. The expert consensus guideline series optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 2003; 64: 1100.
  • 19
    Kutas M, McCarthy G, Donchin E. Augmenting mental chronometry: The P300 as measure of stimulus evaluation time. Science 1997; 197: 792795.
  • 20
    Strik WK, Dierks T, Maurer K. Amplitudes of auditory P300 in remitted and residual schizophrenics: Correlations with clinical features. Neuropsychobiology 1993; 27: 5460.
  • 21
    Polich J. Updating P300: An integrative theory of P3a and P3b. Clin. Neurophysiol. 2007; 118: 21282148.
  • 22
    Uetsuki M. Estimation of premorbid IQ by JART in schizophrenia. Seishin Igaku (Clin. Psychiatry) 2006; 48: 1522 (in Japanese).
  • 23
    Loughland CM, Williams LM, Gordon E. Visual scan paths to positive and negative facial emotions in an outpatient schizophrenia sample. Schizophr. Res. 2002; 55: 159170.
  • 24
    Minassian A, Granholm E, Verney S, Perry W. Visual scanning deficits in schizophrenia and their relationship to executive functioning impairment. Schizophr. Res. 2005; 74: 6979.